Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03901339
Title Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Immunomedics, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

Eribulin

Gemcitabine

Vinorelbine

Capecitabine

Sacituzumab govitecan-hziy

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.